PLYMOUTH MEETING, Pa.,
Oct. 26, 2020 /PRNewswire/
-- INOVIO (NASDAQ: INO) announced today that third quarter
2020 financial results will be released after the market close on
November 9, 2020. Following the
release, the Company will host a live conference call and webcast
at 4:30 p.m. ET to discuss financial
results and provide a general business update regarding its DNA
Medicines Platform, including the company's ongoing vaccine
developments for COVID-19.
A live and archived version of the audio presentation will be
available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with
analysts.
About INOVIO's DNA Medicines Platform
INOVIO has 15 DNA medicine clinical programs currently in
development focused on HPV-associated diseases, cancer, and
infectious diseases, including coronaviruses associated with MERS
and COVID-19 diseases being developed under grants from the
Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S.
Department of Defense. DNA medicines are composed of optimized DNA
plasmids, which are small circles of double-stranded DNA that are
synthesized or reorganized by a computer sequencing technology and
designed to produce a specific immune response in the body.
INOVIO's DNA medicines deliver optimized plasmids directly into
cells intramuscularly or intradermally using INOVIO's proprietary
hand-held smart device called CELLECTRA®. The simple-to-use
CELLECTRA device provides a brief electrical pulse to reversibly
open small pores in the local skin area cells resulting in more
than a hundred-fold increase in product delivery providing dose
sparing and consistency. Once inside the cell, the DNA plasmids
instruct the cell to produce the targeted antigen. The antigen is
processed naturally in the cell and triggers specific T cell and
antibody-mediated immune responses. Administration with the
CELLECTRA device, which takes only a few seconds, is designed to
ensure that the DNA medicine is efficiently delivered directly into
the body's cells, where it can go to work to drive the immune
responses. INOVIO's DNA medicines are transient, and do not
interfere with or change in any way an individual's own DNA. The
advantages of INOVIO's DNA medicine platform are how fast DNA
medicines can be designed and manufactured; the stability of the
products, which do not require freezing in storage and transport;
and the consistent immune response, safety profile, and
tolerability that have been observed in clinical trials with
multiple products.
With more than 2,000 patients receiving INOVIO investigational
DNA medicines in more than 7,000 applications across a range of
clinical trials, INOVIO has a strong track record of rapidly
generating DNA medicine candidates with potential to meet urgent
global health needs.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to
market precisely designed DNA medicines to treat and protect people
from infectious diseases, cancer, and diseases associated with HPV.
INOVIO is the first and only company to have clinically
demonstrated that a DNA medicine can be delivered directly into
cells in the body via a proprietary smart device to produce an
efficacious, robust and tolerable immune response. Specifically,
INOVIO's lead candidate VGX-3100, currently in Phase 3 trials for
precancerous cervical dysplasia, destroyed and cleared high-risk
HPV 16 and 18 in a Phase 2b clinical
trial. High-risk HPV is responsible for 70% of cervical cancer, 91%
of anal cancer, and 69% of vulvar cancer. Also in development are
programs targeting HPV-related cancers and a rare HPV-related
disease, recurrent respiratory papillomatosis (RRP);
non-HPV-related cancers glioblastoma multiforme (GBM) and prostate
cancer; as well as externally funded infectious disease DNA vaccine
development programs in Zika, Lassa fever, Ebola, HIV, and
coronaviruses associated with MERS and COVID-19 diseases. Partners
and collaborators include Advaccine, ApolloBio Corporation,
AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for
Epidemic Preparedness Innovations (CEPI), Defense Advanced Research
Projects Agency (DARPA)/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense
(JPEO-CBRND)/Department of Defense (DOD), HIV Vaccines Trial
Network, International Vaccine Institute (IVI), Medical CBRN
Defense Consortium (MCDC), National Cancer Institute, National
Institutes of Health, National Institute of Allergy and Infectious
Diseases, Ology Bioservices, the Parker Institute for Cancer
Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm
BioLogics, Roche/Genentech, Thermo Fisher Scientific, University of Pennsylvania, VGXI, Walter Reed Army
Institute of Research, and The Wistar Institute. INOVIO also is a
proud recipient of 2020 Women on Boards "W" designation recognizing
companies with more than 20% women on their board of directors. For
more information, visit www.inovio.com.
CONTACTS:
Investors: Ben
Matone, 484-362-0076, ben.matone@inovio.com
Media: Jeff Richardson,
267-440-4211, jrichardson@inovio.com
View original
content:http://www.prnewswire.com/news-releases/inovio-to-report-third-quarter-2020-financial-results-on-november-9-2020-301159344.html
SOURCE INOVIO Pharmaceuticals, Inc.